Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS EXPRESS		NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:41:04 ON 17 MAY 2007

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:41:22 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8
DICTIONARY FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561417b.str





chain nodes :
10 11 12 13 14 15 16 17 18 21 28
ring nodes :
1 2 3 4 5 6 7 8 22 23 24 25 26 27
chain bonds :
1-18 2-16 2-17 4-21 6-14 6-15 7-12 7-13 8-10 8-11 18-22 27-28
ring bonds :
1-2 1-6 2-3 3-4 3-8 4-5 5-6 5-7 7-8 22-23 22-27 23-24 24-25 25-26
26-27
exact/norm bonds :
1-2 1-6 1-18 2-3 3-4 4-5 4-21 5-6 18-22 22-23 22-27 23-24 24-25 25-26
26-27
exact bonds :
2-16 2-17 3-8 5-7 6-14 6-15 7-8 7-12 7-13 8-10 8-11 27-28
isolated ring systems :

containing 1 :

G1:O,S,N

G2:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 21:CLASS
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 10:41:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 16335 TO ITERATE

100.0% PROCESSED 16335 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

L2 7 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 10:41:58 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 16 May 2007 (20070516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2 full

L3 5 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1154707 CAPLUS
DOCUMENT NUMBER: 142:94018
TITLE: Preparation of novel 8-azabicyclo[3.2.1]octane derivatives for use in pharmaceutical compositions as monoamine neurotransmitter re-uptake inhibitors
INVENTOR(S): Peters, Dan; Eriksen, Birgitte L.; Nielsen, Elsebet Ostergaard; Scheel-Krueger, Jorgen; Olsen, Gunnar M.
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113334	A1	20041229	WO 2004-EP51167	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249441	A1	20041229	AU 2004-249441	20040618
CA 2530023	A1	20041229	CA 2004-2530023	20040618
EP 1638965	A1	20060329	EP 2004-741837	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1798745	A	20060705	CN 2004-80015575	20040618
BR 2004011608	A	20060808	BR 2004-11608	20040618
US 2006142331	A1	20060629	US 2005-561417	20051219
NO 2006000360	A	20060324	NO 2006-360	20060123

PRIORITY APPLN. INFO.:		
DK 2003-939	A	20030624
US 2003-482566P	P	20030626
DK 2003-1487	A	20031009
US 2003-509808P	P	20031010
DK 2004-228	A	20040213
US 2004-544210P	P	20040213
WO 2004-EP51167	W	20040618

OTHER SOURCE(S): MARPAT 142:94018
GI



AB 8-Azabicyclo[3.2.1]octane derivs. of tropine and pseudotropine, such as I [R = H, alkyl; R1 = aryl, heteroaryl; X = O, S, NR3; R3 = H, alkyl, acyl, sulfonyl, etc.], were prepared for therapeutic use in the treatment of diseases, disorders or conditions responsive to inhibition of monoamine neurotransmitter reuptake in the central nervous system (CNS). The CNS disorders claimed for treatment include mood disorder, depression, atypical depression, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, posttraumatic stress disorder, acute stress disorder, drug addiction, drug misuse, cocaine abuse, nicotine abuse, tobacco abuse and alcoholism. Further, the CNS disorders claimed for treatment include pain, chronic pain, inflammatory pain, neuropathic pain, migraine pain, tension-type headache, chronic tension-type headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, postoperative pain, post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically-maintained pain, trigeminal neuralgia, dental pain, myofacial pain, phantom-limb pain, bulimia, premenstrual syndrome, late luteal phase syndrome, posttraumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress incontinence, urge incontinence, nocturnal incontinence, sexual dysfunction, premature ejaculation, erectile difficulty, erectile dysfunction, eating disorders, anorexia nervosa, sleep disorders, autism, mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain damage, stroke-induced neuronal damage or Gilles de la Tourette's disease. Thus, endo-8-azabicyclo[3.2.1]octane derivative II was prepared in 33% yield by reacting tropine with tetrahydrothiophene using t-BuOK and 18-crown-6 ether in DMF. Dosages and pharmaceutical compns. of these 8-azabicyclo[3.2.1]octanes were discussed.

IT 817198-69-9P, exo-3-(6-Hydroxypyridin-2-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane 817198-70-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 8-azabicyclo[3.2.1]octane tropine or pseudotropine derivs. for use in pharmaceutical compns. as monoamine neurotransmitter re-uptake inhibitors)

RN 817198-69-9 CAPLUS

CN 2(1H)-Pyridinone, 6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 817198-70-2 CAPLUS
CN 2(1H)-Pyridinone, 6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817198-69-9
CMF C13 H18 N2 O2

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:534173 CAPLUS
DOCUMENT NUMBER: 141:89016
TITLE: Preparation of benzimidazolylazabicyclooctylethylpiperidines as Ccr5 antagonists for the treatment of HIV infection
INVENTOR(S): Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph; Bifulco, Neil; Boros, Eric Eugene; Chauder, Brian Andrew; Chong, Pek Yoke; Duan, Maosheng; Deanda, Felix, Jr.; Koble, Cecilia Suarez; Mclean, Ed Williams; Peckham, Jennifer Poole; Perkins, Angilique C.; Thompson, James Benjamin; Vanderwall, Dana
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA; et al.; et al.
SOURCE: PCT Int. Appl., 859 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054974	A2	20040701	WO 2003-US39644	20031212
WO 2004054974	A3	20040902		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509711	A1	20040701	CA 2003-2509711	20031212
AU 2003300902	A1	20040709	AU 2003-300902	20031212
EP 1569646	A2	20050907	EP 2003-813419	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017230	A	20051025	BR 2003-17230	20031212
CN 1744899	A	20060308	CN 2003-80109628	20031212
JP 2006511554	T	20060406	JP 2004-560838	20031212
NO 2005002739	A	20050819	NO 2005-2739	20050607
US 2006229336	A1	20061012	US 2005-538144	20050609
IN 2005KN01328	A	20060630	IN 2005-KN1328	20050711
PRIORITY APPLN. INFO.:			US 2002-433634P P	20021213
			WO 2003-US39644 W	20031212

OTHER SOURCE(S): MARPAT 141:89016
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I [R1 = (optionally substituted) alkyl, aryl, heteroaryl, carbocyclyl; R2 = H, (optionally substituted) alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroarylalkyl, heteroarylcycloalkyl, aralkylcarbonyl, heteroarylsulfinyl; R3 = H, halo, cyano, trifluoromethyl, (optionally substituted) amino, acylamino, alkyl; X = C1-5 alkylene, optionally substituted with oxo or thioxo groups or halogen atoms, and optionally containing 1-3 oxygen, nitrogen, sulfur, or phosphorus atoms; Y = carbonyl, thiocarbonyl, 1,2-dioxoethylene, oxyalkylcarbonyl, sulfinyl, sulfonyl, oxycyanoimino, (optionally substituted) aminocarbonyl, carbonylamino, aminothiocarbonyl, oxyiminomethyl, thioiminomethyl, amino(cyanoimino)methyl, (cyanoimino)methyl, amino(acylimino)methyl, amino(sulfonylimino)methyl, amino(sulfinylimino)methyl, amino(alkoxyimino)methyl, amino(imino)methyl, (cyanoimino)methoxy, iminomethoxy, (cyanoimino)methanethiyl, alkylcarbonyloxy; A = saturated, partially saturated, or aromatic monocyclic ring with 5-6 atoms or a bicyclic ring with 8-10 members containing 0-5 nitrogen, oxygen, and/or sulfur atoms] such as II are prepared I are prepared as Ccr5 antagonists for the treatment of viral infections, (particularly HIV infection), related syndromes such as AIDS-related complex (ARC), progressive generalized lymphadenopathy, Kaposi's sarcoma, and neurol. conditions, and other diseases such as multiple sclerosis, rheumatoid arthritis, Crohn's disease, and immune-mediated disorders. The invention compds. have pIC50 values of ≥5 in assays for Ccr5 antagonism. Piperidineacetaldehyde III is prepared in four steps from 4-phenyl-4-piperidinecarbonitrile by protection of the piperidine with Boc anhydride, reduction of the nitrile with diisobutylaluminum hydride, Wittig olefination with methoxymethylphosphonium chloride, and hydrolysis of the

enol ether with catalytic p-toluenesulfonic acid monohydrate. The hydrochloride of endo-(benzimidazolyl)azabicyclooctane IV is prepared in five steps from tert-Bu endo-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate; reductive amination with benzylamine, reductive cleavage of the benzyl group by palladium-mediated hydrogenation, a nucleophilic aryl substitution reaction with 1-fluoro-2-nitrobenzene, reduction of the nitro group by hydrogenation over palladium on carbon, and treatment with tri-Et orthoacetate followed by treatment with hydrochloric acid in ethanol. Coupling of III and IV by reductive amination with sodium triacetoxyborohydride, cleavage of the Boc group with hydrochloric acid in dioxane, and acylation with pivaloyl chloride and triethylamine yields II.

IT 716359-09-0P 716359-10-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

RN 716359-09-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[(3-nitro-2-pyridinyl)amino]-, 1,1-dimethylethyl ester, (3-endo)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 716359-10-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[(3-amino-2-pyridinyl)amino]-, 1,1-dimethylethyl ester, (3-endo)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:91257 CAPLUS
DOCUMENT NUMBER: 138:385389
TITLE: p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones
AUTHOR(S): Hunt, Julianne A.; Kallashi, Florida; Ruzek, Rowena D.; Sinclair, Peter J.; Ita, Ida; McCormick, Sherrie X.; Pivnichny, James V.; Hop, Cornelis E. C. A.; Kumar, Sanjeev; Wang, Zhen; O'Keefe, Stephen J.; O'Neill, Edward A.; Porter, Gene; Thompson, James E.; Woods, Andrea; Zaller, Dennis M.; Doherty, James B.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck & Co., Inc.,

Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(3), 467-470
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:385389
GI



I

AB A series of C7-piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones were synthesized as highly potent inhibitors of both p38 mitogen-activated protein (MAP) kinase activity and tumor necrosis factor (TNF)-α release. The 4-aminopentamethylpiperidine naphthyridinone I, which was designed to block metabolism at major 'hot spots', combined excellent inhibitory potency with good oral bioavailability in the rat.

IT 527680-16-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of piperidine and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones as inhibitors of p38 MAP kinase and TNF-α release)

RN 527680-16-6 CAPLUS

CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:574925 CAPLUS
DOCUMENT NUMBER: 137:140442
TITLE: Preparation of 1,5-diaryl-7-heterocyclyl(alkyl)-2-quinolinones as p38 protein kinase inhibitors
INVENTOR(S): Doherty, James B.; Stelmach, John E.; Chen, Meng-Hsin; Liu, Luping; Hunt, Julianne A.; Ruzek, Rowena D.; Goulet, Joung L.; Wisnoski, David D.; Natarajan, Swaminathan Ravi; Rupprecht, Kathleen M.; Bao, Jianming; Miao, Shouwu; Hong, Xingfang
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 440 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058695	A1	20020801	WO 2001-US48676	20011214
WO 2002058695	A9	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431904	A1	20020801	CA 2001-2431904	20011214
AU 2002246677	A1	20020806	AU 2002-246677	20011214
EP 1345603	A1	20030924	EP 2001-994260	20011214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521892	T	20040722	JP 2002-559029	20011214
US 2003092712	A1	20030515	US 2001-23231	20011217
US 6809199	B2	20041026		

PRIORITY APPLN. INFO.:		
US 2000-256822P	P	20001220
WO 2001-US48676	W	20011214

OTHER SOURCE(S): MARPAT 137:140442
GI



I

AB Title compds. were prepared Thus, 2,6-dibromo-4-methoxytoluene was converted in 5 steps to arylquinolinone I (R1 = Br, R2 = OMe) which was condensed with 2,4-F2C6H3B(OH)2 and the O-demethylated product converted in 4 steps to I (R1 = C6H3F2-2,4, R2 = 4-piperidinyl). Data for biol. activity of title compds. were given.

IT 444661-83-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,5-diaryl-7-heterocyclyl(alkyl)-2-quinolinones as p38 protein kinase inhibitors)

RN 444661-83-0 CAPLUS

CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:618101 CAPLUS
DOCUMENT NUMBER: 127:278207
TITLE: Preparation of 4-aminopyrimidine derivatives as antitumor agents.
INVENTOR(S): Himmelsbach, Frank; Dahmann, Georg; Von Ruden, Thomas; Metz, Thomas
PATENT ASSIGNEE(S): Dr. Karl Thomae G.m.b.H., Germany; Himmelsbach, Frank; Dahmann, Georg; Von Ruden, Thomas; Metz, Thomas
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732881	A1	19970912	WO 1997-EP1057	19970303
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19608631	A1	19970911	DE 1996-19608631	19960306
DE 19629652	A1	19980129	DE 1996-19629652	19960723
CA 2243994	A1	19970912	CA 1997-2243994	19970303
AU 9719251	A	19970922	AU 1997-19251	19970303
AU 710274	B2	19990916		
EP 885226	A1	19981223	EP 1997-907066	19970303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1212695	A	19990331	CN 1997-192787	19970303
BR 9708312	A	19990803	BR 1997-8312	19970303
HU 9901820	A2	19990928	HU 1999-1820	19970303
NZ 331546	A	20000327	NZ 1997-331546	19970303
JP 2000506847	T	20000606	JP 1997-531444	19970303
NO 9804084	A	19980904	NO 1998-4084	19980904

PRIORITY APPLN. INFO.:	DE 1996-19608631	A	19960306
	DE 1996-19629652	A	19960723
	WO 1997-EP1057	W	19970303

OTHER SOURCE(S): CASREACT 127:278207; MARPAT 127:278207
GI



I

AB Title compds. [I; R1 = H, Me; R2 = (substituted) Ph, phenylalkyl; AB = NCR3CH:CH, CH:NCR3CH, etc.; R3 = (substituted) morpholino, piperazinyl, oxopiperazinyl, azetidinyl, pyrrolidinyl, piperidinyl, azacycloheptyl], were prepared Thus, 4-[(3-chloro-4-fluorophenyl)amino]-7-(4-amino-1-piperidinyl)pyrido[4,3-d]pyrimidine (preparation given) was heated with 4-aminopyrimidine in Me2CHOH to give 4-[(3-chloro-4-fluorophenyl)amino]-7-(4-amino-1-piperidinyl)pyrido[4,3-d]pyrimidine. I inhibited epidermal growth factor-induced cell proliferation with IC50 = 0.001-0.30 μM.

IT 196796-64-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aminopyrimidine derivs. as antitumor agents)

RN 196796-64-2 CAPLUS

CN Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(4-amino-3,5-dibromophenyl)-N6-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 10:41:04 ON 17 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 10:41:22 ON 17 MAY 2007
L1              STRUCTURE UPLOADED
L2            7 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:41:58 ON 17 MAY 2007
L3            5 S L2 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    27.76     200.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.90      -3.90

STN INTERNATIONAL LOGOFF AT 10:43:58 ON 17 MAY 2007
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS EXPRESS		NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:36:55 ON 17 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:37:04 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8
DICTIONARY FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561417A.str





chain nodes :
10 11 12 13 14 15 16 17 18 21 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 22 23 24 25 26
chain bonds :
1-18 2-16 2-17 4-21 6-14 6-15 7-12 7-13 8-10 8-11 18-22 23-29 24-28
25-27
ring bonds :
1-2 1-6 2-3 3-4 3-8 4-5 5-6 5-7 7-8 22-23 22-26 23-24 24-25 25-26
exact/norm bonds :
1-2 1-6 1-18 2-3 3-4 4-5 4-21 5-6 18-22
exact bonds :
2-16 2-17 3-8 5-7 6-14 6-15 7-8 7-12 7-13 8-10 8-11 22-23 22-26 23-24
23-29 24-25 24-28 25-26 25-27
isolated ring systems :

containing 1 : 22 :

G1:O,S,N

G2:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 21:CLASS
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:37:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:37:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18 TO ITERATE

100.0% PROCESSED 18 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 10:37:54 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 16 May 2007 (20070516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:408584 CAPLUS
DOCUMENT NUMBER: 115:8584
TITLE: Preparation of 2-piperidino-1-alkanol derivatives as antiischemic agents
INVENTOR(S): Chenard, Bertrand Leo
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 398578	A2	19901122	EP 1990-304975	19900509
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
SK 279476	B6	19981104	SK 1990-2328	19890517
CZ 284342	B6	19981014	CZ 1990-2328	19900511
CA 2016860	C	19980728	CA 1990-2016860	19900515
US 5185343	A	19930209	US 1991-784446	19911023
FI 113645	B1	20040531	FI 1991-5403	19911115
US 5272160	A	19931221	US 1992-932844	19920820
US 5338754	A	19940816	US 1993-96913	19930723
US 5391742	A	19950221	US 1994-228466	19940415
US 5710168	A	19980120	US 1994-336639	19941109
US 5527912	A	19960618	US 1995-411030	19950327

PRIORITY APPLN. INFO.:	WO 1989-US2176	A	19890517
	WO 1990-US292	A	19900116
	US 1991-784446	A3	19911023
	US 1992-932844	A3	19920820
	US 1993-96913	A3	19930723
	US 1994-228466	A2	19940415
	US 1994-336639	A3	19941109

OTHER SOURCE(S): CASREACT 115:8584; MARPAT 115:8584
GI



I



II



III

AB The title compds. (I; R = H, alkyl, alkenyl, alkynyl; X = H, OH, aryl; Y = H, OH; Y1 = aryl, aralkyl, arylthio, aryloxy, YY1 = arylmethylene, aralkylmethylene; Q = S, CH:CH), useful as antiischemic agents in treating strokes, Alzheimer's disease, Huntington's disease, and Parkinson's disease (no data), are prepared A mixture of piperidine derivative II, p-(Me2CH)3SiOC6H4COCHBrMe, and Et3N in EtOH was refluxed to give 23% propiophenone III, which was reduced with LiAlH4 to give 89% mixture of (1R*,2S*)- and (1S*,2S*)-I [R = Me, X = 4-(Me2CH)3SiO, YY1 = PhCH, Q = CH:CH] (IV). Hydrolysis of IV with Bu4N+ F- in THF at room temperature gave the mixture phenolic alc. (1S*,2S*)- and (1R*,2S*)-I (R = Me, X = 4-HO, YY1 = PhCH, Q = CH:CH). Also prepared were 75 addnl. I and intermediates.

IT 134138-54-8P 134234-08-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiischemic agent)

RN 134138-54-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-ethanol, α-(4-hydroxyphenyl)-β-methyl-3-(2-thienylthio)-, stereoisomer (9CI) (CA INDEX NAME)



RN 134234-08-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-ethanol, α-(4-hydroxyphenyl)-β-methyl-3-(2-thienylthio)-, stereoisomer (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:36:55 ON 17 MAY 2007)

FILE 'REGISTRY' ENTERED AT 10:37:04 ON 17 MAY 2007
L1 STRUCTURE UPLOADED
L2 0 S L1

```
L3             2 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:37:54 ON 17 MAY 2007
L4             1 S L3 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.74     178.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.78      -0.78

STN INTERNATIONAL LOGOFF AT 10:38:26 ON 17 MAY 2007
```